Author

C. Di Giorgio

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Assay:metabolomics· 1

Frequent Co-Authors

A. Zampella· 4 shared E. Distrutti· 4 shared M. Biagioli· 4 shared M. Bordoni· 4 shared R. Bellini· 4 shared S. Fiorucci· 4 shared B. Catalanotti· 3 shared G. Urbani· 3 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. Zampella

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A microbial derived bile acid acts as GPBAR1 agonist and RORγt inverse agonist and reverses inflammation in inflammatory bowel disease

M. Biagioli, C. Di Giorgio, C. Massa, S. Marchiano', R. Bellini, M. Bordoni, G. Urbani, R. Roselli, G. Lachi, E. Morretta, F. Dal Piaz, B. Charlier, B. Fiorillo, B. Catalanotti, L. Cari, , S. Fiorucci

This study identifies 3-oxo-DCA as a microbial bile acid that acts as a GPBAR1 agonist and RORγt inverse agonist, reversing inflammation in IBD.

bioRxiv · Apr 8, 2024 · PreprintImmunology

Bile Acids Serve As Endogenous Antagonists Of The Leukemia Inhibitory Factor (LIF) Receptor in Oncogenesis

C. Di Giorgio, E. Morretta, A. Lupia, R. Bellini, C. Massa, G. Urbani, M. Bordoni, S. Marchiano, P. Rapacciuolo, C. Finamore, V. Sepe, M. C. Monti, F. Monarca, N. Natalizi, L. Graziosi, , S. Fiorucci

The paper shows bile acids, specifically GDCA, inhibit LIFR in gastric cancer, suggesting potential for bile acid-based therapies in LIF-driven oncogenesis.

bioRxiv · Sep 30, 2023Cancer Biology

Next generation sequencing analysis of gastric cancer identifies the leukemia inhibitory factor receptor (LIFR) as a driving factor in gastric cancer progression and as a predictor of poor prognosis

C. Di Giorgio, S. Marchiano, E. Marino, M. Biagioli, R. Roselli, M. Bordoni, R. Bellini, G. Urbani, A. Zampella, E. Distrutti, A. Donini, L. Graziosi, S. Fiorucci

This study identifies LIFR as a key driver in gastric cancer progression and a predictor of poor prognosis through RNA-seq analysis of patient samples.

bioRxiv · May 5, 2022 · PreprintCancer Biology

Discovery of a AhR flavonoid agonist that counter-regulates ACE2 expression in rodent models of inflammation and attenuates ACE2-SARS-CoV2 interaction in vitro

M. Biagioli, S. Marchiano, R. Roselli, C. Di Giorgio, R. Bellini, M. Bordoni, A. Gidari, S. Sabbatini, D. Francisci, B. Fiorillo, B. Catalanotti, E. Distrutti, A. Carino, A. Zampella, G. Costantino, S. Fiorucci

This study identifies pelargonidin, a flavonoid that reduces ACE2 expression and SARS-CoV2 binding in inflamed colons via AhR activation.

bioRxiv · Feb 24, 2021Pharmacology & Toxicology